452
POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
M. Dimopoulosa, K. Weiselb, P. Moreauc, L.D.A. Jrd, D. Whitee, J.S. Miguelf, P. Sonneveldg, M. Engelhardth, M. Jenneri, A. Corsoj, J. Dürigk, M. Pavicl, M. Salomom, E. Casaln, R. Jiangn, T. Nguyenn, T. Pelusoo, P. Richardsonp
a National and Kapodistrian University of Athens, Athens, Greece
b Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
c University Hospital Hôtel-Dieu, Nantes, France
d UT Southwestern Medical Center, Dallas, United States
e Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada
f Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain
g Erasmus MC Cancer Institute, Rotterdam, the Netherlands
h Universitätsklinikum Freiburg, Freiburg, Germany
i Southampton General Hospital, Southampton, United Kingdom
j Division of Hematology, Hospital of Legnano, Legnano, Italy
k University Hospital Essen, Essen, Germany
l Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, Canada
m Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
n Bristol Myers Squibb, Princeton, United States
o Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
p Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
Ver másLido
2663
Vezesque se leu este artigo
1232
Total PDF
1431
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 19 | 5 | 24 |
| 2025 5 | 58 | 17 | 75 |
| 2025 4 | 35 | 18 | 53 |
| 2025 3 | 46 | 15 | 61 |
| 2025 2 | 41 | 19 | 60 |
| 2025 1 | 35 | 17 | 52 |
| 2024 12 | 44 | 15 | 59 |
| 2024 11 | 36 | 22 | 58 |
| 2024 10 | 35 | 23 | 58 |
| 2024 9 | 23 | 22 | 45 |
| 2024 8 | 26 | 34 | 60 |
| 2024 7 | 19 | 19 | 38 |
| 2024 6 | 23 | 19 | 42 |
| 2024 5 | 22 | 25 | 47 |
| 2024 4 | 24 | 18 | 42 |
| 2024 3 | 28 | 21 | 49 |
| 2024 2 | 18 | 23 | 41 |
| 2024 1 | 20 | 21 | 41 |
| 2023 12 | 23 | 24 | 47 |
| 2023 11 | 41 | 31 | 72 |
| 2023 10 | 17 | 29 | 46 |
| 2023 9 | 24 | 31 | 55 |
| 2023 8 | 14 | 15 | 29 |
| 2023 7 | 18 | 14 | 32 |
| 2023 6 | 29 | 17 | 46 |
| 2023 5 | 31 | 9 | 40 |
| 2023 4 | 13 | 9 | 22 |
| 2023 3 | 32 | 13 | 45 |
| 2023 2 | 18 | 15 | 33 |
| 2023 1 | 16 | 14 | 30 |
| 2022 12 | 29 | 21 | 50 |
| 2022 11 | 26 | 15 | 41 |
| 2022 10 | 21 | 21 | 42 |
| 2022 9 | 29 | 22 | 51 |
| 2022 8 | 26 | 20 | 46 |
| 2022 7 | 23 | 25 | 48 |
| 2022 6 | 20 | 22 | 42 |
| 2022 5 | 25 | 29 | 54 |
| 2022 4 | 16 | 20 | 36 |
| 2022 3 | 20 | 21 | 41 |
| 2022 2 | 14 | 28 | 42 |
| 2021 1 | 14 | 24 | 38 |
| 2021 12 | 16 | 22 | 38 |
| 2021 11 | 15 | 24 | 39 |
| 2021 10 | 34 | 38 | 72 |
| 2021 9 | 21 | 32 | 53 |
| 2021 8 | 29 | 24 | 53 |
| 2021 7 | 26 | 41 | 67 |
| 2021 6 | 17 | 28 | 45 |
| 2021 5 | 16 | 28 | 44 |
| 2021 4 | 52 | 53 | 105 |
| 2021 3 | 45 | 36 | 81 |
| 2021 2 | 19 | 13 | 32 |
| 2020 1 | 15 | 11 | 26 |
| 2020 12 | 17 | 25 | 42 |
| 2020 11 | 18 | 15 | 33 |
Mostrar tudo
